<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

The prolactinoma

Name: The prolactinoma
Creator: COLAO, ANNAMARIA
Keywords: Antineoplastic Agents, 3. Good health, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Withholding Treatment, Drug Resistance, Neoplasm, Pregnancy, prolactinoma, Dopamine Agonists

descriptionPublicationkeyboard_double_arrow_right Article 01 Oct 2009 Italy English Publisher:Elsevier BVJournal:Best Practice & Research Clinical Endocrinology & Metabolism, volume 23, pages 575-596 (issn: 1521-690X,

Authors: COLAO, ANNAMARIA;

doi: 10.1016/j.beem.2009.05.003

pmid: 19945024

handle: 11588/378201

The prolactinoma

- Summary
- Subjects
- Metrics

Abstract

This review focus on the epidemiology, diagnosis and treatment of prolactinomas. In particular, attention was given to recent data showing a high prevalence of these tumours in the general population, 3-5 times higher than previously reported. The diagnosis of hyperprolactinaemia has been simplified in recent years, and only prolactin (PRL) assay and magnetic resonance imaging of the sella are required. Nonetheless, macroprolactinaemia should be assessed in patients with hyperprolactinaemia in the absence of clinical symptoms of elevated PRL levels. The recent evidence that medical therapy with dopamine agonists should be continued lifelong has been confirmed by several studied. The patients achieving disappearance of the tumours and suppression of PRL levels during treatment are those showing the highest likelihood to have persistent remission of hyperprolactinaemia after treatment withdrawal.

Country

Italy

Related Organizations

University Federico II of Naples
Italy

Keywords

Antineoplastic Agents, Treatment Outcome, Withholding Treatment, Drug Resistance, Neoplasm, Pregnancy, prolactinoma, Dopamine Agonists, Humans, Female, Pituitary Neoplasms, Prolactinoma, Pregnancy Complications, Neoplastic

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	139
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%